1. Alphs HH, Gambhira R, Karanam B et al (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105(15):5850–5855
2. Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369(9576):1861–1868
3. Ault KA, Giuliano AR, Edwards RP et al (2004) A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22(23–24):3004–3007
4. Barbara A Slade, Laura Leidel, Claudia Vellozzi, Emily Jane Woo, Wei Hua, Andrea Sutherland, Hector S Izurieta, Robert Ball, Nancy Miller, M Miles Braun, Lauri E Markowitz John Iskander Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine JAMA. 2009;302(7):750–757
5. Bell JA, Sundberg JP, Ghim S et al (1994) A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62:194–198